fda glp-1 compounding warning letters october 2025 News Archives – Partnership for Safe Medicines The FDA Just Sent 25

At present, bariatric surgery (BS) is considered the benchmark treatment of morbid obesity, with well-established indications providing effective long-term outcomes [2, 3] that lead to sustained weight loss [4] and improvement in most weight-related comorbidities [5,6,7], with relatively low morbidity and mortality [8,9,10]

Take the Assessment GLP-1 side effects are primarily gastrointestinal: nausea, vomiting, diarrhea, constipation, and decreased appetite

It will be used strictly for in vitro research activities and in accordance with all relevant local, state, and federal laws and regulations

Looking forward, disease-responsive nanovesicles that release riboflavin in the presence of ROS or acidic pH are being engineered to fine-tune local dosing while minimizing systemic exposure (93)